Overview

A Dose-Escalation Study to Determine the Maximum Tolerated Dose of Arbaclofen Placarbil in Subjects With Alcohol Use Disorder

Status:
Completed

Trial end date:
2016-01-01

Target enrollment:

Participant gender:

Summary

This study will determine the maximum tolerated dose (MTD) of arbaclofen placarbil (AP) in the treatment of subjects with Alcohol Use Disorder (AUD). For every two subjects receiving AP, one subject will receive placebo.

Phase:

Phase 2

Details

Lead Sponsor:

Indivior Inc.

Treatments:

Arbaclofen placarbil
Baclofen
Ethanol